SBPWG:Gaps

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
(Gap Seed List)
Line 1: Line 1:
{{SBPWG Temp}}
{{SBPWG Temp}}
-
===Introduction===
+
==Introduction==
We intend to use this space to seed, prioritize and sustain a list of  'Top 10 gaps' in our practice of synthetic biology for this group - and others - to consider, discuss, and work towards addressing.  We ideally hope to produce from the discussions documented and materials collected here a series of simple, digestible co-authored papers summarizing each gap, current practices, open questions, and recommendations for moving forward.
We intend to use this space to seed, prioritize and sustain a list of  'Top 10 gaps' in our practice of synthetic biology for this group - and others - to consider, discuss, and work towards addressing.  We ideally hope to produce from the discussions documented and materials collected here a series of simple, digestible co-authored papers summarizing each gap, current practices, open questions, and recommendations for moving forward.
-
===Gaps to Mind===
+
==Gap Seed List==
-
Please use this space to suggest and describe new or existing gaps, needs or issues in our practice of synthetic biology. Please add any relevant information, articles, contacts or other resources.
+
===About the Gap Seed List and Editing Methodology===
-
====Gap Seed List====
+
The gaps below were first outlined by participants of the June 30th 2011 Working Group Meeting. This is a rough draft and should be considered a living document to be revised (or re-conceived!) as the contributors see fit. Edit ruthlessly, add comments, references, examples, questions - anything that will be helpful. Don't worry about messing anything up - the wiki allows us to revert to old versions!
-
All these to be refined. Edit ruthlessly. Add comments, references, examples - anything that will be helpful!
+
At least one person should indicate they will take the lead for synthesizing comments into a clear, digestible paragraph outlining the gap, current practices and open questions (though everyone should feel free to add content!). Please indicate your chosen gap(s) to take the lead on by placing your name beside 'content lead' - first come first served. If you have additional gaps, or want to combine gaps, please add them to the list bottom of the list as a newly enumerated gap, and also indicate if it represents a split or merge of other gap(s). This is a work in progress, so give it a good shot, but expect the final product to change!  
 +
===Top Gaps===
 +
(NOT currently prioritized)
-
Emergence of DIY & Implications for Safety, Security
+
====0. Relationship between DIY and Synthetic Biology Communities=====
 +
* Content Lead:
* Should there be similar expectations of responsible conduct between institutional and non-institutional actors?
* Should there be similar expectations of responsible conduct between institutional and non-institutional actors?
 +
* How are we held mutually accountable for each others' actions?
-
Preparedness for Syn Bio (-Labeled) Accidents
+
====1. Ownership, Sharing and Innovation - Property Rights Frameworks for Synthetic Biology=====
-
* Do we have a community response plan? Who will be held accountable?
+
* Content Lead:
-
* http://www.nature.com/nbt/journal/v27/n12/full/nbt1209-1109.html
+
* At what level in the abstraction hierarchy of envisioned biological designs should we instill property rights?
 +
* How does IP determine relationships, scaling, dissemination, commercialization of technology?
 +
* How do scientists deal with the fact we're not lawyers? How do we know if and how we should publish and or/share our parts/devices/organisms?
-
Developing Trust in a World of Profits and Secrets
+
====2. Collaboration, Sharing of Parts and the Security / IP implications thereof====
-
* How can we be ambassadors for biosafety when we do not have knowledge of research ongoing at private companies and in secure govt labs?
+
* Content Lead:
 +
* exposure vs scooping
 +
* possibilities for interception of work by national security as in other fields?
 +
* parts registries - whether or not to release consent
 +
* unknown trajectory to privacy
 +
* institutionalization and access (e.g. cocaine available through Sigma to academic labs, not public)
 +
* e.g. of needing confidentiality, ownership agreements w/ labs before they will share their parts (Joe S)
-
Ownership, Sharing and Innovation - Property Rights Frameworks for Synthetic Biology
+
====3. Low National Scientific Literacy as an impediment to Constructive Dialogue around Emerging Technologies====
-
* At what level in the abstraction hierarchy of envisioned biological designs should we instill property rights?
+
* Content Lead:
 +
* decelerating pace of scientific literacy in the US vs other countries
 +
* public perceptions frame tech developments
 +
* what are the best channels of scientific information that reach publics (e.g. blogs, realclimate.org, reddit, quora, Factcheck.org)
 +
* even within community we have a diverse community of new practitioners
 +
* Establishing Meaningful Dialogues with Diverse Stakeholders - How can deliver reliable information about synthetic biology to the publics?
 +
* How can we anticipate and respond proactively to public/societal sentiments on biotechnology?
 +
* e.g. ETC group letter to SB5 concerned that civil society wasn't included
-
Educating and Inspiring Leadership in Pratices
+
====4. Responding to Other Philosophies and Agendas====
-
* How savy should we expect researchers to be wrt the broader context of technology developments?  
+
* Content Lead:
-
* How do deal with generational transfer of knowledge and immigration from a broad array of disciplines?
+
* Perhaps Related to (the same as?) 3, but dealing with explicitly antagonistic agendas (e.g. PETA?)
 +
* How to recognize, respect dissenting views, philosophies, moral frameworks, philosophies - should these impact decision making?
 +
* Are there limits to rational, constructive dialog?  
-
Testing Engineered Biological Designs in the 'Real World'  
+
====5. Risk Analysis Frameworks for Emerging Technologies====
 +
* Content Lead:
 +
* How do we deal with the unknown unknowns? Are we dealing with the known unknowns?
 +
* How can we claim, justify safety of things we haven't yet built?
 +
* How do we frame both risk and opportunity?
 +
* How do we do ecosystem clinical trials?
 +
* If we say it's safe, why should you trust us?
* What are appropriate risk assessment frameworks for intentional & unintentional environmental release?
* What are appropriate risk assessment frameworks for intentional & unintentional environmental release?
* How do we approach regulation of cross-cutting technology platforms spanning multiple disjointed regulatory bodies set primarily by application area?
* How do we approach regulation of cross-cutting technology platforms spanning multiple disjointed regulatory bodies set primarily by application area?
* Can we develop experimental systems for assessing safety?
* Can we develop experimental systems for assessing safety?
-
* e.g. rE.Coli
+
* e.g. rE.Coli - ' safer chassis, but no regulatory framework so hard to commercialize
* e.g. http://trib.com/news/state-and-regional/article_6945effb-0af4-53ab-ba93-af79461f1535.html
* e.g. http://trib.com/news/state-and-regional/article_6945effb-0af4-53ab-ba93-af79461f1535.html
 +
* Risk Governance & SB  report http://www.irgc.org/IMG/pdf/irgc_SB_final_07jan_web.pdf
-
Economic Forecasting for Synthetic Biology Technology Developments
+
====6. Defining 'Poster Children' for Synthetic Biology====
-
* What are our near-term vs long-term deliverables and how does syn bio fit into biotechnology developments at large?
+
* Content Lead:
 +
* We are much better at articulating risks and telling of stories of failures than the past or future successes. This frames our conversation with the public, govt, regulators etc.
 +
* So focused on not being Monsanto, GMOs that our conversations revolve around risk instead of benefits.
 +
* Possibly could details success stories: Insulin, Amyris, Selective Breeding, Antifreeze Tomatoes etc
 +
* How do we relate how SB could touch and improve people's lives?  
-
Establishing Meaningful Dialogues with Diverse Stakeholders
+
====7. Practical Frameworks for Responding to Political Forces/Situtation that Frame Our Work=====
-
* How can companies anticipate and respond proactively to public/soceital sentiments on biotechnology?
+
* Content Lead:
-
* e.g. ETC group letter to SB5
+
* Land Use Politics
 +
* Existing Systems of Belief
 +
 
 +
 
 +
====8. Biotechnology Innovation Roadmap====
 +
* Content Lead:
 +
* Do we have a roadmap outlining near-term and long-term deliverables of synthetic biology, their context wrt other (bio)technologies and where they offer either new application areas and/or more cost effective solutions?
 +
* This would help us and other
 +
* What are the key decision points, areas for investment to accelerate innovation
 +
* Economic Forecasting for Synthetic Biology Technology Developments
 +
 
 +
 
 +
====9. International Collaboration and Competition====
 +
* Content Lead:
 +
* How do we coordinate between countries re: regulation, safety, security?
 +
* How to balance competition, collaboration - where and how should we invest?
 +
* The internet changes everything
 +
 
 +
 
 +
====10. Education, Training and Identity Across a Diverse Community of Practitioners===
 +
* Content Lead: Megan
 +
* How savy should we expect researchers to be wrt the broader context of technology developments?
 +
* How do we engage and inspire leadership on practices in a way that aligns with our technical goals, interests?  
 +
* How do deal with generational transfer of knowledge and immigration from a broad array of disciplines?
 +
 
 +
 
 +
====11. Preparedness for Syn Bio (-Labeled) Accidents ====
 +
* Content Lead:
 +
* Mistakes will happen. Accidents will happen. Somebody can be expected to misused this technology -  Do we have a community response plan? Who will be held accountable?
 +
* http://www.nature.com/nbt/journal/v27/n12/full/nbt1209-1109.html
 +
 
 +
 
 +
====12. Technology Distribution and Accessibility - Justice ====
 +
* Content Lead:
 +
* How do we develop the technology so that it doesn't serve/benefit only the privileged, elite?
 +
 
 +
 
 +
====13. Developing Trust in a World of Profits and Secrets ====
 +
* Content Lead:
 +
* Relation to 2, 5
 +
* How can we be ambassadors for biosafety when we do not have knowledge of research ongoing at private companies and in secure govt labs?
 +
 
 +
===Prioritization - My Gaps and Your Gaps===
 +
Participants at the Working Group Meeting were asked to list their top 2 gaps that 'somebody' should be resolving, and which amongst those they felt were their responsibility
-
How can deliver reliable information about synthetic biology to the publics?
+
'''Gaps Someone Should Mind'''
-
* e.g. FactCheck.org for synthetic biology as recommended by the PCSBI
+
0.  
-
* e.g. Climate Scientists Page: http://www.realclimate.org/
+
1. JS, JV, DTE, AK
 +
2.
 +
3. RR, JS, JV, DTE, MF, AK
 +
4.
 +
5.RR. SA
 +
6.
 +
7.
 +
8.MP
 +
9.
 +
10. MF, MP
 +
11.
 +
12. JV, SA
 +
13.
-
Risk Governance
+
'''Gaps I Should Mind'''
-
* http://www.irgc.org/IMG/pdf/irgc_SB_final_07jan_web.pdf
+
0.
 +
1. DTE
 +
2. JS ( already affected, part collab), RR, DTE
 +
3. JS (educator), RR, JV++, DTE, AK
 +
4.
 +
5. RR, SA
 +
6. DTE
 +
7.
 +
8. MP
 +
9.
 +
10. MP
 +
11.
 +
12.
 +
13.

Revision as of 18:58, 1 July 2011

Home        About        Members        Meetings        Gaps        Discussion        Resources       



Contents

Introduction

We intend to use this space to seed, prioritize and sustain a list of 'Top 10 gaps' in our practice of synthetic biology for this group - and others - to consider, discuss, and work towards addressing. We ideally hope to produce from the discussions documented and materials collected here a series of simple, digestible co-authored papers summarizing each gap, current practices, open questions, and recommendations for moving forward.

Gap Seed List

About the Gap Seed List and Editing Methodology

The gaps below were first outlined by participants of the June 30th 2011 Working Group Meeting. This is a rough draft and should be considered a living document to be revised (or re-conceived!) as the contributors see fit. Edit ruthlessly, add comments, references, examples, questions - anything that will be helpful. Don't worry about messing anything up - the wiki allows us to revert to old versions!

At least one person should indicate they will take the lead for synthesizing comments into a clear, digestible paragraph outlining the gap, current practices and open questions (though everyone should feel free to add content!). Please indicate your chosen gap(s) to take the lead on by placing your name beside 'content lead' - first come first served. If you have additional gaps, or want to combine gaps, please add them to the list bottom of the list as a newly enumerated gap, and also indicate if it represents a split or merge of other gap(s). This is a work in progress, so give it a good shot, but expect the final product to change!

Top Gaps

(NOT currently prioritized)

0. Relationship between DIY and Synthetic Biology Communities=

  • Content Lead:
  • Should there be similar expectations of responsible conduct between institutional and non-institutional actors?
  • How are we held mutually accountable for each others' actions?


1. Ownership, Sharing and Innovation - Property Rights Frameworks for Synthetic Biology=

  • Content Lead:
  • At what level in the abstraction hierarchy of envisioned biological designs should we instill property rights?
  • How does IP determine relationships, scaling, dissemination, commercialization of technology?
  • How do scientists deal with the fact we're not lawyers? How do we know if and how we should publish and or/share our parts/devices/organisms?


2. Collaboration, Sharing of Parts and the Security / IP implications thereof

  • Content Lead:
  • exposure vs scooping
  • possibilities for interception of work by national security as in other fields?
  • parts registries - whether or not to release consent
  • unknown trajectory to privacy
  • institutionalization and access (e.g. cocaine available through Sigma to academic labs, not public)
  • e.g. of needing confidentiality, ownership agreements w/ labs before they will share their parts (Joe S)


3. Low National Scientific Literacy as an impediment to Constructive Dialogue around Emerging Technologies

  • Content Lead:
  • decelerating pace of scientific literacy in the US vs other countries
  • public perceptions frame tech developments
  • what are the best channels of scientific information that reach publics (e.g. blogs, realclimate.org, reddit, quora, Factcheck.org)
  • even within community we have a diverse community of new practitioners
  • Establishing Meaningful Dialogues with Diverse Stakeholders - How can deliver reliable information about synthetic biology to the publics?
  • How can we anticipate and respond proactively to public/societal sentiments on biotechnology?
  • e.g. ETC group letter to SB5 concerned that civil society wasn't included


4. Responding to Other Philosophies and Agendas

  • Content Lead:
  • Perhaps Related to (the same as?) 3, but dealing with explicitly antagonistic agendas (e.g. PETA?)
  • How to recognize, respect dissenting views, philosophies, moral frameworks, philosophies - should these impact decision making?
  • Are there limits to rational, constructive dialog?


5. Risk Analysis Frameworks for Emerging Technologies

  • Content Lead:
  • How do we deal with the unknown unknowns? Are we dealing with the known unknowns?
  • How can we claim, justify safety of things we haven't yet built?
  • How do we frame both risk and opportunity?
  • How do we do ecosystem clinical trials?
  • If we say it's safe, why should you trust us?
  • What are appropriate risk assessment frameworks for intentional & unintentional environmental release?
  • How do we approach regulation of cross-cutting technology platforms spanning multiple disjointed regulatory bodies set primarily by application area?
  • Can we develop experimental systems for assessing safety?
  • e.g. rE.Coli - ' safer chassis, but no regulatory framework so hard to commercialize
  • e.g. http://trib.com/news/state-and-regional/article_6945effb-0af4-53ab-ba93-af79461f1535.html
  • Risk Governance & SB report http://www.irgc.org/IMG/pdf/irgc_SB_final_07jan_web.pdf


6. Defining 'Poster Children' for Synthetic Biology

  • Content Lead:
  • We are much better at articulating risks and telling of stories of failures than the past or future successes. This frames our conversation with the public, govt, regulators etc.
  • So focused on not being Monsanto, GMOs that our conversations revolve around risk instead of benefits.
  • Possibly could details success stories: Insulin, Amyris, Selective Breeding, Antifreeze Tomatoes etc
  • How do we relate how SB could touch and improve people's lives?


7. Practical Frameworks for Responding to Political Forces/Situtation that Frame Our Work=

  • Content Lead:
  • Land Use Politics
  • Existing Systems of Belief


8. Biotechnology Innovation Roadmap

  • Content Lead:
  • Do we have a roadmap outlining near-term and long-term deliverables of synthetic biology, their context wrt other (bio)technologies and where they offer either new application areas and/or more cost effective solutions?
  • This would help us and other
  • What are the key decision points, areas for investment to accelerate innovation
  • Economic Forecasting for Synthetic Biology Technology Developments


9. International Collaboration and Competition

  • Content Lead:
  • How do we coordinate between countries re: regulation, safety, security?
  • How to balance competition, collaboration - where and how should we invest?
  • The internet changes everything


=10. Education, Training and Identity Across a Diverse Community of Practitioners

  • Content Lead: Megan
  • How savy should we expect researchers to be wrt the broader context of technology developments?
  • How do we engage and inspire leadership on practices in a way that aligns with our technical goals, interests?
  • How do deal with generational transfer of knowledge and immigration from a broad array of disciplines?


11. Preparedness for Syn Bio (-Labeled) Accidents


12. Technology Distribution and Accessibility - Justice

  • Content Lead:
  • How do we develop the technology so that it doesn't serve/benefit only the privileged, elite?


13. Developing Trust in a World of Profits and Secrets

  • Content Lead:
  • Relation to 2, 5
  • How can we be ambassadors for biosafety when we do not have knowledge of research ongoing at private companies and in secure govt labs?

Prioritization - My Gaps and Your Gaps

Participants at the Working Group Meeting were asked to list their top 2 gaps that 'somebody' should be resolving, and which amongst those they felt were their responsibility

Gaps Someone Should Mind 0. 1. JS, JV, DTE, AK 2. 3. RR, JS, JV, DTE, MF, AK 4. 5.RR. SA 6. 7. 8.MP 9. 10. MF, MP 11. 12. JV, SA 13.


Gaps I Should Mind 0. 1. DTE 2. JS ( already affected, part collab), RR, DTE 3. JS (educator), RR, JV++, DTE, AK 4. 5. RR, SA 6. DTE 7. 8. MP 9. 10. MP 11. 12. 13.

Personal tools